spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  chronic myeloid 

 HSMN NewsFeed - 26 Aug 2022
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Sep 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 17 Jun 2016
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
Biopharmaceuticals Distribution
 HSMN NewsFeed - 2 Jun 2016
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jul 2013
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Jun 2013
Teva’s Lonquex(R)(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jan 2012
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2011
ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2011
Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments
Personalized Medicine Oncology Venture Capital
 HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jun 2010
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2009
Asuragen Signs Development and Worldwide Distribution Agreement with Life Technologies
Diagnostics Oncology Distribution
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2009
ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Sep 2008
DOR BioPharma Forms orBec(R) European Medical Advisory Board
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 May 2008
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Oct 2007
ChemGenex Announces Strategic Restructuring of Company to Focus on Late-Stage Cancer Portfolio
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2007
Clinical Data Supporting Development of ChemGenex's Ceflatonin(R) in Imatinib-Resistant CML Published in Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Abbott Introduces CE-Marked DNA Tests in Europe for the Detection of Chromosomal Abnormalities Associated With Leukemia
Diagnostics Oncology
 HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Aug 2006
ChemGenex Announces Publication Of Two New Clinical Studies Supporting Expanded Opportunity For Ceflatonin(R) Beyond CML To Other Leukemias
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jul 2006
Genzyme Launches New Diagnostic Test for Common Blood Cancer
Diagnositcs Oncology
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Jun 2006
Tranzyme Pharma Appoints Industry Veteran as Senior Vice President of Research and Preclinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2006
Patients With Treatment-Resistant Leukemia Achieve High Responses to Tasigna(R) (nilotinib) in First Published Clinical Trial Results
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2006
Gleevec(R) Sets New Treatment Standard in Chronic Myeloid Leukemia With High Overall Survival, Increasing Response and Decreasing Progression
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2006
Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 May 2006
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2006
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2006
Bioenvision's Evoltra(R) Achieves High Response Rates in Adult AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Mar 2006
Quest Diagnostics Launches the First Tests to Help Doctors Assess Status of Leukemia and Lymphoma in Patients Using Blood Plasma Instead of Bone Marrow
Diagnostics Oncology
 HSMN NewsFeed - 27 Mar 2006
SGX Pharmaceuticals Announces Strategic Collaboration to Develop and Commercialize BCR-ABL Inhibitors for the Treatment of Chronic Myelogenous Leukemia (CML)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Mar 2006
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center Study of KRX-0401 for the Treatment of Refractory Leukemia
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2006
Genzyme Launches Key Test to Monitor Gleevec(R) Resistance
Diagnostics Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 31

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 31 additional stories matching:
chronic myeloid
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.